IRD heads into its May 20 earnings with short interest at its highest level in months and an unusual cluster of insider sells already logged — a charged setup for a $370M gene therapy micro-cap.
Short interest has moved quickly and that is the story this week. SI % of FF jumped 52% over the past week to reach 7.5% of the free float — roughly 2.6 million shares short as of May 12. The build has been almost entirely a May event: shorts were running near 1.6-1.7 million shares through most of April, then accelerated sharply from May 5 onward. Availability in the lending pool is at roughly 122% of current short interest, meaning there are still shares to borrow — the market is not yet technically squeezed. Cost to borrow is modest at 0.58% APR, easing slightly on the week. The ORTEX short score has climbed from 45.7 on May 7 to 60.6 today — a meaningful move in under a week — putting IRD in territory where short pressure is worth watching, even if it has not reached extreme levels.
Options positioning sits firmly in call-dominated territory. The put/call ratio is 0.019, barely above its 20-day average of 0.012 and well below the 52-week high of 0.067. There is virtually no demand for downside protection through options. That divergence — rising shorts in the equity lending market, but call-heavy options flow — is the key tension this week. Either short sellers are positioning against the May 20 print while options traders remain optimistic, or the short build reflects hedging activity rather than directional conviction.
Analyst coverage is almost entirely bullish, though the Street just nudged its targets down slightly. Citizens initiated with a Market Outperform rating and a $12 target on April 28, then trimmed that to $11 this week. Cantor Fitzgerald carries a $15 Overweight target from late March. BTIG, Oppenheimer, Wedbush, and Chardan Capital all have Buy or Outperform ratings, with targets clustered in the $10-$12 range. The mean price target is $10.20 — nearly double the current price of $5.18. The EPS surprise factor score is in the 90th percentile, reflecting a track record of beating estimates. The ORTEX stock score total sits at 64.5, driven by an exceptional momentum percentile above 89. Growth scores jumped sharply from the mid-50s to near 69 around May 8, a shift that has held into this week.
The insider picture deserves attention. On April 23, six executives sold shares simultaneously: the CEO, President, CFO, COO, Chief Scientific Officer, and a Vice President all registered sales on the same date. The transactions were small in aggregate dollar terms — the CEO's sale was roughly $50K, the largest of the group — and the net 90-day insider position is actually positive at just under 79,000 shares. This looks more consistent with planned compensation-linked sales than directional conviction. Still, the timing, with earnings a month out, is worth noting. Earlier in March, the CEO sold a larger block of roughly $127K.
On the earnings reaction front, the past three prints have produced mixed but modest moves. The April 20 event saw the stock fall 7.1% the next day and 11% over five days. The March 30 print produced a 4.6% one-day gain. The March 10 event generated a 5% next-day move before fading. The pattern shows IRD can move meaningfully in either direction around catalysts — the April result is the most recent and the sharpest downside reaction on record in the data.
Institutional ownership is concentrated. Bios Equity Partners holds 23% of shares. Foundation Fighting Blindness trimmed by 4 million shares in December but still holds 7.7%. Nantahala Capital added 1.4 million shares through year-end 2025. Balyasny and Millennium each built fresh positions late in 2025. Vanguard added nearly one million shares through Q1 2026. The ownership structure is tightly held, which amplifies the effect of any short squeeze or institutional repositioning.
The next test is May 20. What to watch is whether the short build continues in the days ahead — and whether any of the bullish Street targets get revised further as analysts digest the upcoming print.
See the live data behind this article on ORTEX.
Open IRD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
